Status:
COMPLETED
Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA)
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
It can be assumed that there is a link between what the patient feels and thinks about his medication and objective measures of disease activity and safety.
Detailed Description
A total of 500 subjects will provide 80% power to test the hypothesis that the absolute value of the correlation between two measures (e.g., BMQ Necessity and DAS28) is ≤ 0.3 (i.e., H0:│r│ ≤ 0.3 ) ver...
Eligibility Criteria
Inclusion
- Patients with RA on stable therapy defined as:
- Etanercept: 1x50 mg/week or 2x25mg/week for at least 1 consecutive year. Adalimumab: 1x40 mg every other week for at least 1 consecutive year. Oral corticosteroids: stable doses for ≥ 12 weeks before baseline Methotrexate: stable doses for ≥ 12 weeks before baseline Other DMARD's: stable doses for ≥ 12 weeks before baseline
Exclusion
- Participation in other clinical or observational trials.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT01432366
Start Date
October 1 2010
End Date
January 1 2015
Last Update
January 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Algemeen Ziekenhuis St Jan
Bruges, Belgium, 8000